ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/25/2026
Back to search
Official data from USPTO
BIOTHEUS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
06/25/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
04/14/2022
Registration date
11/07/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/07/2023
Last transaction
06/25/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
CN
Examiner
HUDSON, TAMARA BREE
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "BIOTHEUS" in stylized font above seven Chinese characters positioned horizontally; to the right of the literal element is the stylized depiction of six curving lines of varying sizes surrounding a single shaded dot.
Holders and representatives
Holders
BioNTech (Zhuhai) Pharmaceuticals R&D Co., Ltd.
Biotheus Inc.
Representatives
Michael T. Smith Birch Stewart Kolasch & Birch LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines used for treating cancers; biological preparations used for treating cancer; anti-cancer pharmaceutical preparations; medicines for human purposes for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases; pharmaceutical preparations for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases; chemico-pharmaceutical preparations for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases; medicines for medical purposes for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases; chemical preparations for pharmaceutical purposes for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases; biological preparations for medical purposes for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases; biochemicial medicines for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases; medicines in the form of injections for the treatment of cancerimmune function affectionnervous system diseasesrespiratory system diseaseshematological system diseasescirculatory system diseaseshypertensive diseasesdiabetic diseasesdigestive system diseasesbone and joint diseasesendocrine and metabolic system diseasesankylosing spondylitis diseasepsoriasislupus erythematosus diseaserheumatoid arthritis diseasesimmunomodulatory diseasesurinary system diseasesskin system diseasesreproductive system diseases
Class 42
Scientific research in the field of medication evaluation; quality control evaluation for others; scientific research in the nature of conducting clinical trials for others; scientific research in the field of antibody; services of medical laboratory
Publications
History of USPTO decisions and trademark events.
27 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/04/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/08/2024
FIMP
FINAL DISPOSITION PROCESSED
02/08/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/07/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
11/07/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/22/2023
PUBO
PUBLISHED FOR OPPOSITION
08/22/2023
GPNX
NOTIFICATION PROCESSED BY IB
08/21/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/02/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/02/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/14/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/13/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/13/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/13/2023
RFNT
REFUSAL PROCESSED BY IB
04/19/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/30/2023
RFRR
REFUSAL PROCESSED BY MPU
03/30/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/08/2023
CNRT
NON-FINAL ACTION WRITTEN
02/07/2023
DOCK
ASSIGNED TO EXAMINER
02/01/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/10/2022
MAFR
APPLICATION FILING RECEIPT MAILED
07/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/08/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/07/2022
Continuous trademark protection
Get notified about every new filing that threatens BIOTHEUS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.